Bolanle Akinlade

12.2k total citations · 5 hit papers
51 papers, 1.8k citations indexed

About

Bolanle Akinlade is a scholar working on Physiology, Dermatology and Immunology. According to data from OpenAlex, Bolanle Akinlade has authored 51 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Physiology, 26 papers in Dermatology and 19 papers in Immunology. Recurrent topics in Bolanle Akinlade's work include Asthma and respiratory diseases (30 papers), Dermatology and Skin Diseases (26 papers) and IL-33, ST2, and ILC Pathways (16 papers). Bolanle Akinlade is often cited by papers focused on Asthma and respiratory diseases (30 papers), Dermatology and Skin Diseases (26 papers) and IL-33, ST2, and ILC Pathways (16 papers). Bolanle Akinlade collaborates with scholars based in United States, France and Germany. Bolanle Akinlade's co-authors include Gianluca Pirozzi, Neil M.H. Graham, Laurent Eckert, Diamant Thaçi, Allen Radin, Z. Chen, A. Gadkari, Heribert Staudinger, Marius Ardeleanu and Brad Shumel and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Bolanle Akinlade

50 papers receiving 1.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

2017 344 citations Marjolein de Bruin‐Weller, Diamant Thaçi et al. British Journal of Dermatology profile →
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

2019 231 citations Gil Yosipovitch, Laurent Eckert et al. British Journal of Dermatology profile →
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

2023 119 citations Gil Yosipovitch, Nicholas Mollanazar et al. Nature Medicine profile →
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

2024 102 citations Klaus F. Rabe, Alberto Papi et al. profile →
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

2024 65 citations Marcus Maurer, Thomas B. Casale et al. Journal of Allergy and Clinical Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bolanle Akinlade United States	20	1.1k	911	805	419	298	51	1.8k
Oliviero Rossi Italy	18	265 0.2×	434 0.5×	460 0.6×	195 0.5×	175 0.6×	60	1.1k
Nikhil Amin United States	19	280 0.2×	950 1.0×	1.1k 1.4×	223 0.5×	377 1.3×	80	1.9k
Y. King United Kingdom	12	157 0.1×	756 0.8×	318 0.4×	152 0.4×	95 0.3×	14	1.2k
Francesca Saretta Italy	14	145 0.1×	229 0.3×	132 0.2×	182 0.4×	69 0.2×	54	690
A. Soria France	17	444 0.4×	179 0.2×	69 0.1×	195 0.5×	31 0.1×	86	970
Sun-Sin Kim South Korea	16	127 0.1×	219 0.2×	320 0.4×	71 0.2×	340 1.1×	43	1.1k
Michael E. Weiss United States	13	174 0.2×	265 0.3×	287 0.4×	42 0.1×	111 0.4×	20	813
Tara F. Carr United States	19	67 0.1×	289 0.3×	776 1.0×	78 0.2×	563 1.9×	48	1.3k
Andrew J. MacGinnitie United States	14	88 0.1×	302 0.3×	152 0.2×	99 0.2×	68 0.2×	40	643
Lucia Liotti Italy	16	109 0.1×	276 0.3×	106 0.1×	109 0.3×	50 0.2×	60	667

Countries citing papers authored by Bolanle Akinlade

Since Specialization

Citations

This map shows the geographic impact of Bolanle Akinlade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bolanle Akinlade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bolanle Akinlade more than expected).

Fields of papers citing papers by Bolanle Akinlade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bolanle Akinlade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bolanle Akinlade. The network helps show where Bolanle Akinlade may publish in the future.

Co-authorship network of co-authors of Bolanle Akinlade

This figure shows the co-authorship network connecting the top 25 collaborators of Bolanle Akinlade. A scholar is included among the top collaborators of Bolanle Akinlade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bolanle Akinlade. Bolanle Akinlade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benedetti, Fabrizio De, Ivan Foeldvari, Nadina Rubio‐Pérez, et al.. (2025). Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and 1‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study. Arthritis Care & Research.

Bacharier, Leonard B., Ian Pavord, Jorge Máspero, et al.. (2024). Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma. Journal of Allergy and Clinical Immunology. 154(1). 101–110. 23 indexed citations

Maurer, Marcus, Thomas B. Casale, Sarbjit S. Saini, et al.. (2024). Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of Allergy and Clinical Immunology. 154(1). 184–194. 65 indexed citations breakdown →

Simpson, Eric L., Jonathan I. Silverberg, Margitta Worm, et al.. (2024). Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. 90(6). 1190–1199. 21 indexed citations

Máspero, Jorge, Alessandro Fiocchi, A. Deschildre, et al.. (2024). Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics. The Journal of Allergy and Clinical Immunology In Practice. 12(11). 3135–3138.e2. 1 indexed citations

Schmidt, Wolfgang, Bhaskar Dasgupta, Angeliki Giannelou, et al.. (2023). A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Research & Therapy. 25(1). 199–199. 16 indexed citations

Bacharier, Leonard B., Theresa W. Guilbert, Constance H. Katelaris, et al.. (2023). Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study. The Journal of Allergy and Clinical Immunology In Practice. 12(4). 948–959. 12 indexed citations

Yosipovitch, Gil, Nicholas Mollanazar, Sonja Ständer, et al.. (2023). Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nature Medicine. 29(5). 1180–1190. 119 indexed citations breakdown →

Castro, Mario, Klaus F. Rabe, Jonathan Corren, et al.. (2020). Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Research. 6(1). 204–2019. 38 indexed citations

10.

Cork, Michael J., Diamant Thaçi, Lawrence F. Eichenfield, et al.. (2020). Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology. 184(5). 857–870. 50 indexed citations

11.

Silverberg, Jonathan I., Eric L. Simpson, Marius Ardeleanu, et al.. (2019). Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. British Journal of Dermatology. 181(1). 80–87. 44 indexed citations

12.

Eichenfield, Lawrence F., Thomas Bieber, Lisa A. Beck, et al.. (2019). Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American Journal of Clinical Dermatology. 20(3). 443–456. 114 indexed citations

13.

Thaçi, Diamant, Eric L. Simpson, Mette Deleuran, et al.. (2019). Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Journal of Dermatological Science. 94(2). 266–275. 134 indexed citations

14.

Benedetti, Fabrizio De, Inmaculada Calvo Penadés, Alexey Maschan, et al.. (2019). FRI0549 SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY. Annals of the Rheumatic Diseases. 78. 969–970. 5 indexed citations

15.

Davis, John D., Ashish Bansal, David Hassman, et al.. (2018). Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving Dupilumab. Clinical Pharmacology & Therapeutics. 104(6). 1146–1154. 34 indexed citations

16.

Corren, Jonathan, Mario Castro, Jorge Máspero, et al.. (2018). Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. Ghent University Academic Bibliography (Ghent University). PA1124–PA1124. 10 indexed citations

17.

Busse, William W., Jorge Máspero, Dinesh Saralaya, et al.. (2018). Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST. Ghent University Academic Bibliography (Ghent University). PA1125–PA1125. 12 indexed citations

18.

Busse, William W., Jorge Máspero, Klaus F. Rabe, et al.. (2018). Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Advances in Therapy. 35(5). 737–748. 130 indexed citations

19.

Simpson, Eric L., J.‐P. Lacour, Jonathan I. Silverberg, et al.. (2018). Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2). Journal of Allergy and Clinical Immunology. 141(2). AB131–AB131. 2 indexed citations

20.

Blauvelt, Andrew, Melinda Gooderham, Peter Foley, et al.. (2017). P67: LONG‐TERM MANAGEMENT OF MODERATE‐TO‐SEVERE ATOPIC DERMATITIS WITH DUPILUMAB AND CONCOMITANT TOPICAL CORTICOSTEROIDS: A 1‐YEAR RANDOMIZED, PLACEBO‐CONTROLLED PHASE 3 TRIAL (CHRONOS). Internal Medicine Journal. 47(S5). 25–25. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact